Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2014
At a glance
- Drugs Amsilarotene (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 08 Apr 2011 Planned End Date changed from 1 Nov 2011 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 24 Jul 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.